Acute pancreatitis during GLP-1 receptor agonist treatment. A case report
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 receptor agonists (GLP-1RA) are the newest treatment for diabetes mellitus (DM). These drugs can down-regulate fasting glucose more than oral drugs and lead to more constant glucose levels compared to regular insulin. Acute pancreatitis is a serious condition that may have a fatal outcome. It has been shown that long term and high doses of GLP-1RA can cause pancreatic changes in animals, but no connection has been proven in humans. We present the case of a 67 years old man with DM treated with oral drugs for 10 years until 3 months before, when GLP-1RA was added. He presented progressive abdominal pain, vomiting, and increased level of serum lipase and amylase were found. Ultrasonography and computed tomography found pancreatic and peripancreatic fatty tissue inflammation (inflammation score 2, necrosis score 0). All the etiologies of acute pancreatitis (lithiasis, alcohol, autoimmune, or trauma) were excluded. After GLP-1RA cessation and supportive treatment the evolution was self-limited with full recovery within 5 days. We concluded that acute pancreatitis can be considered a side effect of the GLP-1 treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Standards of Medical Care in Diabetes—2012
(2012) · Diabetes Care · doi:10.2337/dc12-s011 · Cited by 2,240
Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Riddle, M. C., Forst, T., Aronson, R., Sauque-Reyna, L., Souhami, E., Silvestre, L., Ping, L., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2462 · Cited by 253
Do GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B. L., Díaz, R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509255 · Cited by 131
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123
Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus.
Christensen, M., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2009) · PubMed · Cited by 84
Research works printed but not linked: 1
- [9]ELIXA trial show CV safety of lixisenatide Available from: https://www.escardio.org/The-ESC/Press-Office/Press-releases/elixa-trial-shows-cv-safety-of-lixisenatide
Cited by
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
“Early observational studies (Chis & Fodor, 2017; Elashoff et al., 2011) reported an increased risk of pancreatitis or pancreatic cancer when patients were treated with GLP-1 receptor agonist.”
BackgroundLiu, L., Chen, J., Wang, L., Chen, C., & Chen, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043789 · Cited by 258
Kuang, M., Li, J., Yang, X., Yang, L., Xu, J., Yan, S., Lv, Y.-F., Ren, F., Hu, J., & Zhou, J. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116326 · Cited by 153
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports
Shetty, R., Basheer, F. T., Poojari, P. G., Thunga, G., Chandran, V. P., & Acharya, L. D. (2022) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102427 · Cited by 145
Wolfe, D. M., Kanji, S., Yazdi, F., Barbeau, P., Rice, D. B., Beck, A., Butler, C., Esmaeilisaraji, L., Skidmore, B., Moher, D., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231883 · Cited by 118
Metadata
- Authors
- Chis, B. A., & Fodor, D.
- Affiliations
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- ORCID
- Fodor, Daniela
- Venue
- Medicine and Pharmacy Reports
- Publisher
- Clujul Medical
- Published
- 2018-01-30
- Volume
- 91
- Issue
- 1
- Pages
- 117-119
- ISSN
- 2602-0807 (ISSN-L)
- 2668-0572
- PMC
- PMC5808258
- OpenAlex
- W2614450769
- Semantic Scholar
- 2eddd4d10016b9532ec76125d52cb8edadc29285
- Cited by
- 26
- References
- 13
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 4 · 2023: 1 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 2 · 2018: 1
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Medicine and Pharmacy Reports (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- acute pancreatitis, GLP-1 receptor agonists, glucagon-like peptide-1, drug-induced pancreatitis, adverse drug reactions, diabetes mellitus, pancreatitis, drug discontinuation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acute pancreatitis during GLP-1 receptor agonist treatment. A case report. https://app.cochat.ai/papers/10.15386/cjmed-804
- The paper
- Chis, B. A., & Fodor, D. (2018). Acute pancreatitis during GLP-1 receptor agonist treatment. A case report. Medicine and Pharmacy Reports. https://doi.org/10.15386/cjmed-804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

